<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="letter" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17150</article-id><article-id pub-id-type="doi">10.36691/RJA17150</article-id><article-id pub-id-type="edn">MMVZXG</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Letters to the editor</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Письма в редакцию</subject></subj-group><subj-group subj-group-type="article-type"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Beyond basic hydration: multidirectional components of emollients plus for the control of atopic dermatitis symptoms (Expert Council Resolution dated December 18, 2025)</article-title><trans-title-group xml:lang="ru"><trans-title>За рамками базисного увлажнения: разнонаправленные компоненты эмолентов плюс для контроля симптомов атопического дерматита (резолюция Совета экспертов от 18 декабря 2025 г.)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2252-8570</contrib-id><contrib-id contrib-id-type="spin">5906-9724</contrib-id><name-alternatives><name xml:lang="en"><surname>Murashkin</surname><given-names>Nikolay N.</given-names></name><name xml:lang="ru"><surname>Мурашкин</surname><given-names>Николай Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>m_nn2001@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5044-5265</contrib-id><contrib-id contrib-id-type="spin">1107-4372</contrib-id><name-alternatives><name xml:lang="en"><surname>Kruglova</surname><given-names>Larisa S.</given-names></name><name xml:lang="ru"><surname>Круглова</surname><given-names>Лариса Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>kruglovals@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6378-8582</contrib-id><contrib-id contrib-id-type="spin">9094-9688</contrib-id><name-alternatives><name xml:lang="en"><surname>Araviyskaya</surname><given-names>Elena R.</given-names></name><name xml:lang="ru"><surname>Аравийская</surname><given-names>Елена Роальдовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>arelenar@mail.ru</email><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3875-4030</contrib-id><contrib-id contrib-id-type="spin">1053-3290</contrib-id><name-alternatives><name xml:lang="en"><surname>Lvov</surname><given-names>Andrey N.</given-names></name><name xml:lang="ru"><surname>Львов</surname><given-names>Андрей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>alvov@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7610-6061</contrib-id><contrib-id contrib-id-type="spin">6807-7137</contrib-id><name-alternatives><name xml:lang="en"><surname>Sokolovskiy</surname><given-names>Evgeny V.</given-names></name><name xml:lang="ru"><surname>Соколовский</surname><given-names>Евгений Владиславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>s40@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0238-6563</contrib-id><contrib-id contrib-id-type="spin">3827-0100</contrib-id><name-alternatives><name xml:lang="en"><surname>Shatokhina</surname><given-names>Eugenia A.</given-names></name><name xml:lang="ru"><surname>Шатохина</surname><given-names>Евгения Афанасьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>e.a.shatokhina@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central State Medical Academy</institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center for Children’s Health</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр здоровья детей</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">I.P. Pavlov First Saint Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">GALAKTIKA Beauty Institute</institution></aff><aff><institution xml:lang="ru">Институт красоты «ГАЛАКТИКА»</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет имени М.В. Ломоносова</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="preprint" publication-format="electronic" iso-8601-date="2026-09-22"><day>22</day><month>09</month><year>2026</year></pub-date><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-10-14"><day>14</day><month>10</month><year>2026</year></pub-date><pub-date date-type="collection"><year>2026</year></pub-date><volume>23</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>391</fpage><lpage>398</lpage><history><date date-type="received" iso-8601-date="2026-08-04"><day>04</day><month>08</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-09-17"><day>17</day><month>09</month><year>2026</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2026-08-04"><day>04</day><month>08</month><year>2026</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2026-09-17"><day>17</day><month>09</month><year>2026</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-10-14"><day>14</day><month>10</month><year>2026</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, АБВ-пресс</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-10-14"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/17150">https://rusalljournal.ru/raj/article/view/17150</self-uri><abstract xml:lang="en"><p>A scientific meeting in the format of an expert council was held on December 18, 2025, in Moscow and focused on the practical aspects and prospects of using an updated lipid-replenishing balm with antipruritic action. The discussion focused on current scientific concepts regarding the skin microbiome and its crucial role in the mechanisms underlying chronic dermatological disorders, particularly atopic dermatitis.</p> <p>Current understanding of emollients extends beyond basic hydration: products in the “emollients plus” category, owing to additional non-pharmacological components, provide antipruritic, antimicrobial, and anti-inflammatory effects. At the same time, there is no generally accepted classification that physicians can rely on when selecting such a product, although emollients plus remain a basic recommendation for atopic dermatitis of any severity.</p> <p>Aim — to review the key mechanisms involved in the pathogenesis of atopic dermatitis and the targets of individual components of basic-care products that determine the rational choice of an emollient plus, using an updated lipid replenishing balm with anti-itch actions as an example.</p> <p>The review successively addresses skin-barrier impairment and the “outside-in” and “inside-out” hypotheses; the pathophysiology of the itch-scratch cycle and the concept of the neurobiome, which combines the antiprotease fraction and a filamentous bacterium lysate and microresyl from <italic>Ophiopogon japonicus</italic> plant extract; alterations in the skin microbiome associated with overcolonization by <italic>Staphylococcus aureus</italic> and the potential for their correction with postbiotics; qualitative and structural imbalances in stratum corneum lipids and principles of its replenishment; and the synergistic effects of emollients plus and topical corticosteroids, including their steroid-sparing effect. The multi-target active complex is shown to act on interconnected mechanisms involved in the pathogenesis of atopic dermatitis and itch, including inhibition of the PAR2, PAR4, TRPV1, and MRGPR receptors. The choice of an emollient plus should be based on the spectrum and concentration of its additional active components and on the evidence base of the particular product; the renewed lipid replenishing balm with anti-itch action meets these requirements, which justifies its use in patients with atopic dermatitis for faster disease control.</p></abstract><trans-abstract xml:lang="ru"><p>Научное мероприятие в формате консилиума экспертов состоялось 18 декабря 2025 г. (Москва) и было посвящено практическим аспектам и перспективам применения обновленного липидовосполняющего бальзама с противозудным действием. В фокусе дискуссии оказались современные научные представления о микробиоме кожи и его решающей роли в механизмах развития хронических дерматологических патологий, в первую очередь атопического дерматита.</p> <p>Современные представления об эмолентах выходят за рамки базисного увлажнения: средства категории «эмоленты плюс» за счет дополнительных нефармакологических компонентов оказывают противозудное, антимикробное и противовоспалительное действие. При этом общепринятой классификации, на которую врач мог бы опираться при выборе такого средства, не существует, тогда как эмоленты плюс остаются базовой рекомендацией при атопическом дерматите любой степени тяжести.</p> <p>Цель работы — рассмотреть ключевые звенья патогенеза атопического дерматита и точки приложения отдельных компонентов средств базисного ухода, определяющие рациональный выбор эмолента плюс, на примере обновленного липидовосполняющего бальзама с противозудным действием. Последовательно проанализированы нарушения кожного барьера и гипотезы «снаружи-внутрь» и «изнутри-наружу»; патофизиология цикла «зуд-расчесы» и понятие нейробиома, объединяющее антипротеазную фракцию, лизат нитчатой бактерии и экстракт растения <italic>Ophiopogon japonicu</italic><italic>s</italic>; изменения микробиома кожи с гиперколонизацией <italic>Staphylococcus aureus</italic> и возможности его коррекции постбиотиками; качественный и структурный дисбаланс липидов рогового слоя и принципы его восполнения; синергизм эмолентов плюс с топическими глюкокортикостероидами и стероидосберегающий эффект. Показано, что многоцелевой активный комплекс нейробиома воздействует на взаимосвязанные звенья патогенеза атопического дерматита и механизмы формирования зуда, включая ингибирование рецепторов PAR2, PAR4, TRPV1 и MRGPR.</p> <p>Выбор эмолента плюс должен основываться на спектре и концентрации дополнительных активных компонентов, а также на доказательной базе конкретного средства; этим требованиям отвечает рассмотренный в статье липидовосполняющий бальзам с противозудным действием, что обосновывает его применение у пациентов с атопическим дерматитом для более быстрого достижения контроля над заболеванием.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>emollient plus</kwd><kwd>skin barrier</kwd><kwd>pruritus</kwd><kwd>skin microbiome</kwd><kwd>neurobiome</kwd><kwd>Staphylococcus aureus</kwd><kwd>ceramide</kwd><kwd>topical corticosteroid</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>эмолент плюс</kwd><kwd>кожный барьер</kwd><kwd>зуд</kwd><kwd>микробиом кожи</kwd><kwd>нейробиом</kwd><kwd>Staphylococcus aureus</kwd><kwd>церамид</kwd><kwd>топический глюкокортикостероид</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The article was prepared with the participation of L’Oréal (La Roche-Posay brand). The company provided authors with product’s information materials.</funding-statement><funding-statement xml:lang="ru">Публикация подготовлена при участии компании L’Oréal (бренд La Roche-Posay): компанией были предоставлены материалы по продукту.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Missaoui S, Gaadi A, Oussama K, et al. The primary mechanisms underlying atopic dermatitis. Tunis Med. 2025;103(1):65–72. doi: 10.62438/tunismed.v103i1.5220 EDN: IPLIDY</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Murashkin NN, Pavlova ES, Epishev RV, et al. Skin microbiome composition and key factors of its barrier function. Current Pediatrics. 2023;22(5):387–392. (In Russ.) doi: 10.15690/vsp.v22i5.2624 EDN: WLXPQC</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(Suppl 8):S115–S123.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hatano Y, Elias PM. “Outside-to-inside”, “inside-to-outside”, and “intrinsic” endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Front Immunol. 2023;14:1239251. doi: 10.3389/fimmu.2023.1239251 EDN: FGMPVZ</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kovaleva YuS, Vedler AA, Kozhevnikova PE. The role of ceramides in preserving the epidermal barrier. Russian Journal of Clinical Dermatology and Venereology. 2019;18(4):513–518. (In Russ.) doi: 10.17116/klinderma201918041513 EDN: VVZPRR</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ch’ng CC. Rebalancing of the skin microbiome with an emollient ’plus’ for effective management of atopic dermatitis: a mini review. Med J Malaysia. 2024;79(2):203–205.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nikolaeva TV, Nikolaev AD. Pathophysiological mechanisms of pruriceptive itching and sensit. Modern Problems of Science and Education. 2024;6. (In Russ.) doi: 10.17513/spno.33804 EDN: HHPSGC</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Балаболкин И.И., Мачарадзе Д.Ш. Наружная терапия атопического дерматита у детей (гидратация, увлажняющие препараты). Педиатрия им. Г.Н. Сперанского. 2005;84(3):78–86. EDN: HRZJHT</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ohya Y. Prevention of atopic dermatitis: what are we missing? Allergy Asthma Immunol Res. 2025;17(4):433–446. doi: 10.4168/aair.2025.17.4.433 EDN: BNAMUB</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Murashkin NN, Opryatin LA, Epishev RV, et al. Pruritus and atopic dermatitis: from etiological features to management. Current Pediatrics. 2020;19(6):468–476. (In Russ.) doi: 10.15690/vsp.v19i6.2151 EDN: GXCEOB</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Камаев А.В., Трусова О.В., Камаева И.А. Зуд при атопическом дерматите у детей: известные механизмы и возможности его долгосрочного контроля. РМЖ. 2015;3:142.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mahe YF, Perez MJ, Tacheau C, et al. A novel Vitreoscilla filiformis extract grown in spa water-enriched media activates endogenous cutaneous antioxidant and antimicrobial defenses via the potent Toll-like receptor 2/protein kinase C zeta transduction pathway. Clin Cosmet Investig Dermatol. 2013;6:191–196. doi: 10.2147/CCID.S47324</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Guéniche A, Dahel K, Bastien P, et al. Vitreoscilla filiformis bacterial extract to improve the efficacy of emollient used in atopic dermatitis symptoms. J Eur Acad Dermatol Venereol. 2007;22(6):746–747. doi: 10.1111/j.1468-3083.2007.02428.x</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Guéniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159(6):1357–1363. doi: 10.1111/j.1365-2133.2008.08836.x</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Olisova OYu, Svitich OA, Potapova MB. The skin microbiome and atopic dermatitis: a review. Russian Journal of Skin and Venereal Diseases. 2021;24(5):443–450. (In Russ.) doi: 10.17816/dv80125 EDN: EAGDKX</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Atopic dermatitis and the microbiome: is there a link? Review of O.B. Tamrazova speech. Consilium Medicum. 2020;22(7):20–24. (In Russ.) doi: 10.26442/20751753.2020.7.200275 EDN: TYJTWU</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang L, Xu L. The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis. Front Pediatr. 2025;13:1498965. doi: 10.3389/fped.2025.1498965 EDN: NIKKMM</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zeichner J, Seité S. From probiotic to prebiotic using thermal spring water. J Drugs Dermatol. 2018;17(6):657–662.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Svirshchevskaya EV, Matushevskaya EV. Role of lipids in skin barrier properties. Russian Journal of Clinical Dermatology and Venereology. 2019;18(3):360–365. (In Russ.) doi: 10.17116/klinderma201918031360 EDN: WIPMWF</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Murashkin NN, Ambarchyan ET, Epishev RV, Materikin AI. Skin barrier properties in norm and pathology. Pediatria n.a. G.N. Speransky. 2015;94(6):165–169. (In Russ.) EDN: VBBOTD</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Fedenko ES, Zakharova IN, Zaytseva OV, et al. Practical issues of using emollients for the prevention of exacerbations of atopic dermatitis during the flowering season: expert resolution. Medical Council. 2023;17:172–178. (In Russ.) doi: 10.21518/ms2023-364 EDN: CFPQWY</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Tamrazova OB, Dubovets NF, Tamrazova AV, Seleznev SP. Role of emollients in the prevention of skin diseases in young children. Medical Council. 2021;1:158–166. (In Russ.) doi: 10.21518/2079-701X-2021-1-158-166 EDN: KUIJZQ</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Namazi MR. Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium. Int Immunopharmacol. 2004;4(6):709–712. doi: 10.1016/j.intimp.2003.11.008</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tanno O, Ota Y, Kitamura N, et al. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143(3):525–531. doi: 10.1111/j.1365-2133.2000.03705.x</mixed-citation></ref></ref-list></back></article>
